Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- P2_ABSSSIIndependent statistical analysis of TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03964493).
- P2PIndependent statistical analysis of CPAP vs ASV for Insomnia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02365064).
- P2P+IYIndependent statistical analysis of An Evaluation of an Integrated Approach to Prevention and Early Intervention in the Elementary School Years: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- P3 Long Term Safety Study of Once Daily SB204 in Acne: Complete Statistical AnalysisIndependent statistical analysis of P3 Long Term Safety Study of Once Daily SB204 in Acne: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- P3: Pacemaker Patient Profiling Study: Complete Statistical AnalysisIndependent statistical analysis of P3: Pacemaker Patient Profiling Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00294060).
- p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246: Complete Statistical AnalysisIndependent statistical analysis of p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- PA 03-103Independent statistical analysis of Controlled Trial of Prenatal Vitamin D3 Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis: Complete Statistical AnalysisIndependent statistical analysis of PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PA21Independent statistical analysis of Study of Phosphate Levels in Patients With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00824460).
- PABCIndependent statistical analysis of Physical Activity Behavior Change for Older Adults After Dysvascular Amputation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02738086).
- PACBACKIndependent statistical analysis of Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PACEIndependent statistical analysis of Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PACEIndependent statistical analysis of Patients With Intermittent Claudication Injected With ALDH Bright Cells: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01774097).
- PACEIndependent statistical analysis of Physical Activity Choices Everyday: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03824769).
- PACE-RBBBIndependent statistical analysis of Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PACERIndependent statistical analysis of Providing Adolescent Contraception in the Emergency Room: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02475980).
- PACIFICIndependent statistical analysis of A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with…
- PACIFIC-5Independent statistical analysis of A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PACIFIC-AFIndependent statistical analysis of Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin…
- PACIFIC-AMIIndependent statistical analysis of Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack: primary endpoint results, effect…
- PACIFYIndependent statistical analysis of Positive Attitudes Concerning Infant Feeding- a Questionnaire for Women Living With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PACK-PMIndependent statistical analysis of Animal Assisted Intervention With Dogs for Children With ADHD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05102344).
- Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01796197).
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors: primary endpoint results, effect estimate with confidence…
- Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Paclitaxel in Treating Patients With Ovarian Stromal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel in Treating Patients With Ovarian Stromal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00006227).
- Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence…
- Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment: primary endpoint…
- Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women): Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04209686).
- Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer: primary endpoint results, effect estimate with…
- PACMAN-IIIndependent statistical analysis of Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01515046).
- Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN): Complete Statistical AnalysisIndependent statistical analysis of Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02410551).
- Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02469415).
- PACSIndependent statistical analysis of Cranberry for UTI Prevention in Residents of Long Term Care Facilities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PACTIndependent statistical analysis of Parent Acceptance and Commitment Therapy (PACT) for Parents of Children With Pediatric Feeding Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PACTIndependent statistical analysis of Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00532493).
- PACU TelemedIndependent statistical analysis of Telemedicine Control Tower for the Post-Anesthesia Care Unit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04020887).
- PADIndependent statistical analysis of Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PADD-ONIndependent statistical analysis of Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen: primary endpoint results, effect estimate with confidence interval, sample-size…
- PADOASUIndependent statistical analysis of In Vitro Diagnostic Test for DOAC in Urine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03182829).
- pAF for the Treatment of Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of pAF for the Treatment of Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04886960).